Phase II Multicentric Trial Maintenance Therapy With 6 Monthly Revlimid Cycles Alternated With 6 Monthly Vidaza Cycles in First CR After Induction LIA Chemotherapy for Elderly (≥ 60) Fit Patients With Poor Prognosis Acute Myeloid Leukemia.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 16 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Azacitidine (Primary) ; Lenalidomide (Primary)
Indications Acute myeloid leukaemia
Focus Therapeutic Use
Acronyms LAMSA-maintenance

Most Recent Events

12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition
03 Mar 2011 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight